◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

NAVCO Pharmaceuticals Inc.

Financial Statements (IFRS) · Amounts in CAD
5 10 All
Income Statement
Balance Sheet
Cash Flow
Line Item FY 2022Sep 30, 2022 FY 2022Jun 30, 2022 FY 2021Jun 30, 2021
Total Revenue -- 0.00 0.00
Operating Revenue -- 0.00 0.00
Selling General And Administration -- 72,430 63,614
General And Administrative Expense -- 72,430 63,614
Other Operating Expenses -- 27,662 15,928
Operating Expense -- 100,092 79,542
Operating Income -- -100,092 -79,542
EBIT -- -100,092 -79,542
Interest Income -- 6,412 5,460
Interest Income Non Operating -- 6,412 5,460
Net Interest Income -- 6,412 5,460
Pretax Income -- -93,680 -74,082
Tax Effect Of Unusual Items -- 0.00 0.00
Net Income From Continuing And Discontinued Operation -- -93,680 -74,082
Net Income From Continuing Operation Net Minority Interest -- -93,680 -74,082
Net Income Including Noncontrolling Interests -- -93,680 -74,082
Net Income Common Stockholders -- -93,680 -74,082
Net Income -- -93,680 -74,082
EBITDA -- -100,092 -79,542
Normalized EBITDA -- -100,092 -79,542
Basic EPS -0.03 -0.04 -0.03
Diluted EPS -0.03 -0.04 -0.03
Basic Average Shares 14.5M 2.6M 2.6M
Diluted Average Shares 14.5M 2.6M 2.6M
Tax Rate For Calcs -- 0.00 0.00
Normalized Income -- -93,680 -74,082
Diluted NI Availto Com Stockholders -- -93,680 -74,082
Net Income Continuous Operations -- -93,680 -74,082
Net Non Operating Interest Income Expense -- 6,412 5,460
Other Gand A -- 72,430 63,614
Total Expenses -- 100,092 79,542
Line Item FY 2022Sep 30, 2022 FY 2022Jun 30, 2022 FY 2021Jun 30, 2021
Cash And Cash Equivalents -- 1,799 12,067
Cash Cash Equivalents And Short Term Investments -- 1,799 12,067
Cash Financial -- 1,799 12,067
Receivables -- 110,372 103,960
Current Assets -- 112,171 116,027
Total Non Current Assets -- 0.00 0.00
Total Assets -- 112,171 116,027
Accounts Payable -- 60,567 10,655
Payables -- 60,567 10,655
Payables And Accrued Expenses -- 108,699 18,875
Current Accrued Expenses -- 48,132 8,220
Current Liabilities -- 108,699 18,875
Total Non Current Liabilities Net Minority Interest -- 0.00 0.00
Total Liabilities Net Minority Interest -- 108,699 18,875
Common Stock -- 315,845 315,845
Capital Stock -- 315,845 315,845
Retained Earnings -- -402,102 -308,422
Common Stock Equity -- 3,472 97,152
Stockholders Equity -- 3,472 97,152
Total Equity Gross Minority Interest -- 3,472 97,152
Total Capitalization -- 3,472 97,152
Net Tangible Assets -- 3,472 97,152
Tangible Book Value -- 3,472 97,152
Working Capital -- 3,472 97,152
Invested Capital -- 3,472 97,152
Share Issued -- 4.6M 4.6M
Ordinary Shares Number -- 4.6M 4.6M
Loans Receivable -- 110,372 103,960
Other Equity Interest -- 89,729 89,729
Line Item FY 2022Sep 30, 2022 FY 2022Jun 30, 2022 FY 2021Jun 30, 2021
Operating Cash Flow -- -10,268 -80,710
Cash Flow From Continuing Operating Activities -- -10,268 -80,710
Change In Working Capital -- 89,824 -1,168
Change In Payables And Accrued Expense -- 89,824 -1,168
Change In Payable -- 49,912 -2,888
Other Non Cash Items -- -6,412 -5,460
Issuance Of Debt -- -- 0.00
Repayment Of Debt -- 0.00 -98,500
Net Issuance Payments Of Debt -- 0.00 -98,500
Financing Cash Flow -- 0.00 -88,500
Cash Flow From Continuing Financing Activities -- 0.00 -88,500
Changes In Cash -- -10,268 -169,210
Beginning Cash Position -- 12,067 181,277
End Cash Position -- 1,799 12,067
Free Cash Flow -- -10,268 -80,710
Change In Account Payable -- 49,912 -2,888
Change In Accrued Expense -- 39,912 1,720
Change In Prepaid Assets -- -- 0.00
Long Term Debt Issuance -- -- 0.00
Long Term Debt Payments -- 0.00 -98,500
Net Income From Continuing Operations -- -93,680 -74,082
Net Long Term Debt Issuance -- 0.00 -98,500
Proceeds From Stock Option Exercised -- 0.00 10,000
NEWS
Loading news...
TRENDING
Loading...